Navigation Links
Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
Date:2/12/2009

CHARLESTON, S.C., Feb. 12 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid-induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced preliminary findings from its development and testing of an Opioid Symptoms Questionnaire, or OSQ, which will be used in Charleston's clinical trials.

"This pilot methodology study was designed to test the feasibility and reliability of the OSQ," reported Dr. Bernard Schachtel, Chief Scientific Officer at Charleston Labs. "All patients used the OSQ before and at intervals after ingesting different opioid drugs to indicate the presence and severity of symptoms caused by these medications.

"Using the OSQ prospectively, showing natural progression of opioid side effects," Dr. Schachtel continued, "patients detected different symptoms, not just nausea or vomiting, in good accordance with conventional methods, occasionally with better sensitivity. We will be presenting the final results from this version of the OSQ and other measurement instruments to our Scientific Advisory Board and the clinical investigators for their review and input before completing the protocol for our full-sized clinical trial."

This methodology study was conducted in preparation for Charleston's studies on patients who may experience OINV, the target indication for Charleston's first opioid drug, CL-108. Arrangements are being made with clinical investigators at major universities and research sites in the US to participate in a multi-centered double-blind, randomized, placebo-controlled, multiple-dose safety and efficacy study on over 1,000 patients with post-operative pain. The purpose of this Phase III study is to evaluate CL-108 for relief of acute moderately severe or severe pain and the reduction or elimination of OINV.

All clinical studies for Charleston Laboratories are being overseen by SRC, Inc., a contract research organization based in Jupiter, Florida, which specializes in clinical trials on patients' symptoms (such as nausea).

About Charleston Laboratories, Inc

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.


'/>"/>
SOURCE Charleston Laboratories, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Doug Flutie, Jr. Foundation Grants NAA $10,000 for Burbacher/Charleston Study
2. The Hope Clinic in Charleston, SC invests in technology to prevent vision loss in patients
3. Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation
4. Charleston Laboratories, Inc. Phase I Clinical Trial
5. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
6. LCA-Vision Conducts 2008 Annual Stockholder Meeting
7. iCRco Conducts First Annual Asia Pacific Distributor Training Program
8. AARP Responds to Senator Grassley, Conducts Comprehensive Review of Marketing of Fixed Benefit Indemnity Products
9. Pennsylvania State Health Department Conducts Pertussis Immunization Clinic in Mercer County
10. NASA Conducts Pilot Cognition Studies
11. New data on hormone therapy must lead to re-evaluation of official guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: